• Embedding digital into pharma's DNA

    Pharmas have increased their interest in digital capabilities, especially for clinical trials and gathering real world evidence, as well as for consumer applications.

  • Augmenting R&D with artificial intelligence

    How can artificial intelligence better analyze research information and outcomes data to improve drug R&D? See our interview with BenevolentBIO CEO Jackie Hunter.

  • Value-based healthcare and Value Labs

    Learn in this In Vivo article how a proposed new approach to value-based contracts could help drive the shift to value-based reimbursements and drug pricing.

  • Life sciences dealmaking expected to continue

    Our Global Capital Confidence Barometer shows that policy reform and portfolio rationalization have heightened dealmaking activity across the life sciences spectrum.

  • Participatory health

    Participatory health is transforming the healthcare industry. We examine shifts in emphasis, direction and focus necessary to realise a new and disruptive paradigm.

  • Australia’s diverted profits tax

    The centralization of intellectual property and functions into regional or global hubs is one of the main drivers of efficiency for life sciences multinational enterprises.

  • Cracking the engaged aging code through technology

    A convergence of technological advancements and trends are already underway that could help make the concept of "healthy aging" a reality.

  • Global Corporate Divestment Study: Life sciences

    How can life sciences companies generate a higher price for divestments and use them to fund growth opportunities? Learn more.

  • The 2017 outlook for life sciences

    Pressure on drug pricing, shifting political forces in key markets and potential tax relief in the US support a positive outlook for 2017 life sciences M&A.

Life Sciences

Finding sustainability in biotechnology, pharmaceutical and medical technology

Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.

Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.

We cover key issues in these areas:




Contact us

Request or call a meeting
If you have a specific service need or inquiry, please contact our Business Development Program Office team.

Tel: +62 21 5289 5672
Tel: +62 21 5289 5136
Tel: +62 21 5289 5138

Connect with us

Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.

EY-Applying IFRS 10 and IFRS 11

Applying IFRS 10 and IFRS 11

How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.

Citizen Today special edition: health care

Citizen Today special edition: health care

Conversations in health care, a special edition, features interviews with health care leaders from around the world.